Kennen MacKay
Stock Analyst
(1.40)
# 4,648
Out of 4,648 analysts
39
Total ratings
46.15%
Success rate
7.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kennen MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $4 → $5 | $2.29 | +118.34% | 1 | Apr 17, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $40 → $42 | $44.83 | -6.31% | 3 | Jun 27, 2023 | |
| AMGN Amgen | Maintains: Sector Perform | $224 → $236 | $316.91 | -25.53% | 4 | Aug 5, 2022 | |
| EXEL Exelixis | Maintains: Outperform | $32 → $31 | $34.29 | -9.59% | 2 | Nov 3, 2021 | |
| ADCT ADC Therapeutics | Maintains: Outperform | $33 → $34 | $3.02 | +1,025.83% | 2 | Nov 3, 2021 | |
| PRTA Prothena Corporation | Maintains: Outperform | $59 → $82 | $16.46 | +398.18% | 5 | Sep 30, 2021 | |
| PBYI Puma Biotechnology | Maintains: Sector Perform | $13 → $6 | $2.95 | +103.39% | 2 | Aug 6, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $87 → $88 | $66.01 | +33.31% | 9 | Jul 29, 2021 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $42 | $25.04 | +67.73% | 1 | Apr 30, 2021 | |
| MESO Mesoblast | Initiates: Sector Perform | $48 | $8.34 | +475.54% | 1 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $175 | $6.04 | +2,797.35% | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $23 | $51.23 | -55.10% | 3 | Apr 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | n/a | $19.94 | - | 3 | Apr 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $0.93 | +1,400.54% | 1 | Sep 15, 2017 |
Nuvation Bio
Apr 17, 2024
Maintains: Outperform
Price Target: $4 → $5
Current: $2.29
Upside: +118.34%
Agios Pharmaceuticals
Jun 27, 2023
Maintains: Outperform
Price Target: $40 → $42
Current: $44.83
Upside: -6.31%
Amgen
Aug 5, 2022
Maintains: Sector Perform
Price Target: $224 → $236
Current: $316.91
Upside: -25.53%
Exelixis
Nov 3, 2021
Maintains: Outperform
Price Target: $32 → $31
Current: $34.29
Upside: -9.59%
ADC Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $33 → $34
Current: $3.02
Upside: +1,025.83%
Prothena Corporation
Sep 30, 2021
Maintains: Outperform
Price Target: $59 → $82
Current: $16.46
Upside: +398.18%
Puma Biotechnology
Aug 6, 2021
Maintains: Sector Perform
Price Target: $13 → $6
Current: $2.95
Upside: +103.39%
BioMarin Pharmaceutical
Jul 29, 2021
Maintains: Sector Perform
Price Target: $87 → $88
Current: $66.01
Upside: +33.31%
Nurix Therapeutics
Apr 30, 2021
Initiates: Outperform
Price Target: $42
Current: $25.04
Upside: +67.73%
Mesoblast
Oct 22, 2020
Initiates: Sector Perform
Price Target: $48
Current: $8.34
Upside: +475.54%
May 8, 2020
Maintains: Outperform
Price Target: $275 → $175
Current: $6.04
Upside: +2,797.35%
Apr 3, 2019
Upgrades: Outperform
Price Target: $18 → $23
Current: $51.23
Upside: -55.10%
Apr 4, 2018
Downgrades: Sector Perform
Price Target: n/a
Current: $19.94
Upside: -
Sep 15, 2017
Initiates: Outperform
Price Target: $14
Current: $0.93
Upside: +1,400.54%